Vimarsana
Biggest News Aggregation in the World

Page 49 - Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Looking Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Looking Statement Today - Breaking & Trending Today

Merck Initiates Phase 3 Clinical program for Oral PCSK9 Inhibitor Candidate MK-0616 - Vimarsana News

Merck Initiates Phase 3 Clinical program for Oral PCSK9 Inhibitor Candidate MK-0616

RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the initiation of the company's Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral...

Clear Blue Technologies Announces Second Quarter Fiscal 2023 Financial Results - Vimarsana News

Clear Blue Technologies Announces Second Quarter Fiscal 2023 Financial Results

TORONTO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Clear Blue Technologies International Inc. (TSXV: CBLU) (FRANKFURT: OYA) (OTCQB: CBUTF), announces it...

Mawson Announces Passing of Director Colin Maclean - Vimarsana News

Mawson Announces Passing of Director Colin Maclean

Mawson Announces Passing of Director Colin Maclean

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616 - Vimarsana News

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

Program plans to enroll approximately 17,000 participants across three global studies ...

Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Vimarsana News

Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)--Aug 25, 2023--